INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world, accounting for approximately 3% of new cancer diagnoses in the United States and >600,000 new cases every year worldwide.
1,2 HNSCC comprises >90% of all head and neck cancers, most often arising from the epithelium of the oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx. 3 Surgery is a standard treatment option for many patients with HNSCC. In the current era, patients often undergo a complex series of tests, evaluations, and referrals before treatment initiation. During this period, patients express anxiety regarding cancer progression, and frequently are reassured by practitioners that any disease progression is likely to be minimal.
Time to treatment initiation (TTI) is a proposed national health care metric in the era of quality-based reimbursement. 4 Previous studies among patients with HNSCC have associated increasing TTI with worsening mortality. 5, 6 This relationship may be multifaceted, with sociodemographic issues, management of comorbid conditions, and complexity of treatment modalities all contributing to increased TTI and decreased overall survival (OS). It is possible that tumor progression contributes minimally to worsening mortality for those patients experiencing treatment delay, and that expediting care through an already stressed health care system may be a misplaced national emphasis. Considering the importance of health care metrics in the era of quality-based care, clarifying the mechanism behind the association between increased TTI and decreased OS is critical. In the current study, we sought to identify a relationship between increased TTI and tumor progression to elucidate the impact that a reduction in TTI may have on outcomes in patients with HNSCC.
MATERIALS AND METHODS

Data Source
The National Cancer Data Base (NCDB) is a nationwide clinical oncology database jointly sponsored by the American College of Surgeons and the American Cancer Society. The NCDB contains hospital registry data regarding malignancies, treatments, and outcomes from >1500 Commission on Cancer-accredited facilities, representing >70% of newly diagnosed cancer cases in the United States and including >34 million historical records since 1985. 7 
Patient Population
For the current study, we queried the NCDB for all patients recorded from 2005 through 2014 with head and neck cancers, and selected tumors originating from anatomic sites most commonly treated with definitive surgery: the oral cavity, oropharynx, larynx, and hypopharynx. The following International Classification of Diseases for Oncology, 3rd Edition site codes were used to confirm patients with HNSCC: 8052, 8070, 8071, 8072, 8073, 8074, 8075, 8076, 8078, 8081, 8083, 8084, 8094, and 8560. To ensure consistent and reliable pathologic staging, only patients undergoing primary definitive surgical resection of the primary tumor site without preoperative radiotherapy (RT) or chemotherapy were included. Patients were excluded if they had distant metastatic disease at the time of diagnosis (stage IVC or cM1), inconsistent TNM and AJCC grouped stage, unknown TTI, or a TTI >365 days. Patients with a TTI of 0 days also were excluded due to concerns regarding accuracy. To examine upstaging, complete clinical and pathologic staging data were required, and therefore patients lacking this complete set of data were excluded; for example, patients without complete clinical and pathologic T classification were excluded from the analyses of T upstaging. For all survival analyses, patients with unknown survival status or follow-up time were excluded; because no survival data were provided for patients diagnosed in 2014, these patients also were excluded from survival analyses.
The current study was exempt from institutional review board approval.
Study Outcomes and Variable Definitions
The primary outcome of the current study was clinical-topathologic upstaging. Three methods were used to measure upstaging: 1) clinical-to-pathologic T category; 2) clinical-to-pathologic N category; and 3) overall grouped stage upstaging. For each method of measuring upstaging, we created a separate subgroup of patients with complete clinical and pathologic staging data. Upstaging was defined in each method as any pathologic level more advanced than the assigned clinical category/stage. Sociodemographic, disease, treatment, and follow-up data were extracted for each patient from the NCDB. Patient comorbidity was assessed using the Charlson Comorbidity Index, reported in the NCDB as the Charlson-Deyo Comorbidity Score, with 3 possible truncated values of 0, 1, or >1. 8, 9 TTI was defined as the time elapsed from the date of diagnosis, based on histologic, cytologic, or immunohistochemical confirmation, to the date of definitive surgery. OS was assessed using the date from diagnosis to death or last follow-up.
Statistical Analysis
To investigate differences between upstaged patients and controls (defined as patients who were not upstaged), demographic, disease, and treatment characteristics first were tabulated and compared using the Pearson chisquare test. Quantitative variables were compared using the Student t test. Next, factors associated with pathologic upstaging were investigated using multivariable logistic regression. Separate regressions were performed for each established subgroup for each type of upstaging. All available covariates were included in each model. In addition to adjusting for TTI categorized into 4 groups of 0 to 30 days, 31 to 60 days, 61 to 90 days, and >90 days, additional separate multivariable regressions were performed with TTI included as a continuous variable using restricted cubic splines with 4 knots to represent a nonlinear relationship between TTI and upstaging. 10 In these analyses, the knots represented points in which the cubic function could change, and the reference relative odds ratio (OR) or relative hazard ratio (HR) was set to equal 1.0 at a TTI of 1 day to best interpret changes with increasing TTI. Finally, the association between upstaging and mortality was investigated using Cox proportional hazards regression, again with and without use of restricted cubic splines. For survival curves, the KaplanMeier method was used to estimate OS and log-rank tests were used to compare survival distributions. All P values <.05 were considered to be statistically significant. All data were analyzed using R statistical software (version 3.4.3; R Foundation for Statistical Computing, Vienna, Austria). patients, 3 cohorts composed of 60,194 patients, 51,380 patients, and 52,980 patients met the inclusion criteria and had complete clinical and pathologic T, N, or stage group data available, respectively. Within these cohorts, survival status and follow-up time were available for 51,672 patients, 44,199 patients, and 45,530 patients, respectively, with complete T, N, or stage group data, thereby establishing our subgroups for survival analysis. A Consolidated Standards Of Reporting Trials diagram detailing the process for establishing these cohorts is shown in Figure 1 .
Characteristics for each of these cohort subsets by upstage status are summarized in Table 1 . N upstaging was most common (18.6%), followed by stage group (17.4%) and T (12.1%) upstaging. The majority of patients, whether upstaged or not, were treated at academic facilities, and upstaged patients were more commonly given adjuvant treatment (P < .001 each for T, N, and stage group). Univariable analysis demonstrated that upstaging was more common in patients with extended TTI, because 64.7% of patients who were T upstaged had a TTI of 4 weeks before receiving definitive surgery, compared with only 57.6% of control patients. This trend was consistent across all types of upstaging and became stronger as the TTI increased (P < .001 for all). The likelihood of clinical-to-pathologic upstaging also was found to vary significantly by age, sex, race, Hispanic ethnicity, insurance status, income, education, Charlson-Deyo Comorbidity Score, year of diagnosis, distance from treatment facility, transition between facilities, cancer site, and clinical staging.
Factors Associated With Upstaging
Multivariable logistic regression for each type of upstaging was performed and adjusted for each covariate (Table 2 ). This demonstrated a multifactorial association between Comorbidity also impacted the likelihood of upstaging. Compared with comorbidity scores of 0, scores of 1 increased the odds of T, N, or stage group upstaging by approximately 10% (P < .01); comorbidity scores of at least 2 significantly increased the odds of T (18%), N (24%), and stage group (31%) upstaging compared with scores of 0 (P < .01). Upstaging also was time-dependent because more recently diagnosed patients were more likely to be upstaged; every additional year since 2005 was associated with a 4% increased odds of T or stage group upstaging or a 2% increased odds of N upstaging (P < .001 for all). Patients treated at community centers demonstrated the lowest risk of upstaging, with at least 25% decreased odds of upstaging compared with academic centers (P < .001), which may relate to the complexity of the case or access to care with a delay in referral time. Furthermore, a transition between care facilities increased the odds of N or stage group upstaging by approximately 10% (P < .01).
Disease factors also were found to be associated with upstaging. Compared with the oral cavity, laryngeal cancers had increased odds of T (OR, 1.67; 95% CI, 1.55- observed for N and stage group upstaging; however, the magnitude of this trend toward increased odds of N and stage group upstaging appeared to plateau after approximately 4 weeks. When we included TTI into the full multivariable models using restricted cubic splines to represent a nonlinear relationship between TTI and upstaging, relative odds of T, N, and stage group upstaging were significantly escalated immediately as the TTI increased (Fig. 2) . Relative odds of T and stage group upstaging continued to grow with increasing TTI to maximums of 2.25 and 1.93, respectively, at 365 days. However, the maximum relative odds for N upstaging was 1.40 at 40 days before slowly declining with further increasing TTI; by this model, TTI was no longer a significant predictor of N upstaging after 183 days.
Relative Effects of Upstaging and TTI on Survival
Kaplan-Meier analysis demonstrated that upstaged patients had significantly poorer OS compared with (Figs. 3A-3C ). Within the T, N, and stage group subgroups, there were 19,260, 16,737, and 17,144 total deaths, respectively. The median survival was significantly decreased for patients who were T (4.70 years vs 7.18 years), N (4.13 years vs 7.37 years), or stage group (5.07 years vs 7.10 years) upstaged (P < .001). Cox proportional hazards regression was used to model OS in the separate settings of potential T, N, or stage group upstaging while adjusting for covariates (Table 3) . Consistent with prior studies, significant predictors of mortality included age; sex; race; Hispanic ethnicity; insurance status; income and education levels; Charlson-Deyo Comorbidity Score; facility type; transition between facilities; primary tumor site; clinical T, N, or stage group; and treatment modality. Unlike with upstaging, the year of diagnosis demonstrated no significant trend toward predicting OS. In addition, in contrast with its relationship with upstaging, a transition between facilities instead predicted approximately a 10% decrease in the relative hazard of mortality in each of the settings of potential T, N, or stage group upstaging (P < .001). Furthermore, although adjuvant therapies all were found to significantly predict increased odds of upstaging, adjuvant RT (HR, 0.86; 95% CI, 0.82-0.89) and CRT (HR, 0.92; 95% CI, 0.88-0.96) instead predicted improved survival within the context of stage group upstaging (P < .001).
Although increasing TTI consistently and significantly predicted T, N, and stage group upstaging, it was not found to be a consistently significant predictor of upstaging all significantly increased the relative hazard of mortality and to a much larger degree than extended TTI (P < .001). When TTI was included in these survival models using restricted cubic splines to represent a nonlinear relationship between TTI and mortality (Figs. 3D-3F), TTI was found to be a significant predictor of increasing mortality within the setting of stage group upstaging. This trend was briefly significant in the setting of N upstaging between TTIs of 95 days and 177 days, but was never found to be significant in the setting of T upstaging.
DISCUSSION
Given the importance of staging in establishing an accurate prognosis in patients with HNSCC, 12, 13 it is critical to understand discrepancies between clinical and pathologic staging to minimize upstaging. In the current study, we found clinical-to-pathologic upstaging to be common in patients with HNSCC. TTI appears to significantly affect the risk of upstaging above the baseline rate inherent with clinical staging, and patients who experience upstaging are at an increased risk of death. Furthermore, TTI is not a consistently significant predictor of mortality after adjusting for upstaging. Taken together, this suggests tumor progression as a mechanism in the previously described complex relationship of decreased survival with increasing TTI in patients with head and neck cancer. 5, 14 To the best of our knowledge, the current understanding of upstaging in patients with HNSCC is limited to a few studies, each constrained by size and scope. Waaijer et al and Jensen et al have reported that the time between diagnostic imaging and RT was associated with tumor progression. 15, 16 Kowalski and Carvalho corroborated these findings for all oncologic treatments. 17 However, these articles all were single-institution retrospective studies with <100 patients and limited generalizability. Despite this consistent trend between time delay and upstaging, to our knowledge the relationship between upstaging and survival remains unclear. Certain studies have found tumor progression to be predictive of mortality. [15] [16] [17] However, recent studies by Choi et al and Biron et al separately observed no significant impact of upstaging on prognosis. 18, 19 We sought to clarify this discrepancy using the power and diversity provided by the NCDB. 7 Although the results of the current study suggest tumor progression as a mechanism for increased mortality with increasing TTI, other factors clearly contribute to increased TTI and mortality. The data presented herein (and prior data) suggest that racial disparities, access to care, income, insurance status, comorbidity, and transfer of care to larger academic centers all are related to increased upstaging. 20, 21 In addition, just as Murphy et al reported increases in TTI in more recent years, 14 we observed that upstaging also has become more frequent in the same timeframe. Each of these covariates provides a window into the complex relationship between TTI, upstaging, and mortality; more advanced tumors requiring surgical expertise in patients with limited resources and social support clearly are associated with increased mortality and will require a longer TTI. These data confirm the long-held concerns of patients that tumor progression is possible if unnecessary delays are introduced into the workup. [22] [23] [24] Although tumor progression (measured herein by pathologic upstaging) is possible, it remains clear that ample time should be taken to make good treatment decisions. This is evidenced by the transition in care covariate and differing results in Tables 2 and 3 . Although a transition between facilities was associated with an increased risk of all 3 forms of upstaging, such transitions also were associated with a decreased risk of mortality, suggesting that the benefits of time spent planning and coordinating complex treatment regimens may outweigh their accompanying delay and associated upstaging.
It is unclear from the results of the current study what the ideal TTI threshold should be, but it appears that even incremental 1-week delays for the first 4 weeks between diagnosis and definitive surgery can be detrimental for both upstaging and mortality. Figure 2 demonstrates that TTI is a continuous covariate with a continuously increasing degree of risk for tumor progression (as measured by upstaging). This is especially significant as wait times for cancer surgery continue to increase, 14, 25 with patients with early-stage disease having the longest surgical wait times as individuals with latestage disease are prioritized. [26] [27] [28] These data suggest that efforts to avoid treatment delays for financial, billing, and scheduling reasons should be strongly considered. Improvements may be possible at the national level through improvements in access to care and with insurance coverage, but also at the institutional level with patient navigators and multidisciplinary workflow optimization.
Finally, the results of the current study suggest that the previously reported relationship between increasing TTI and mortality 5, 14 is indeed largely driven by tumor progression, as measured by upstaging herein. Given the significant relationship between TTI and T, N, and stage group upstaging reported in the current study and the subsequent lack of a consistent association between TTI and mortality in survival models adjusting for upstaging, it appears that TTI itself is not a significant predictor of mortality independent of upstaging. However, the lone observed significant relationship between TTI and mortality within the context of stage group upstaging (Fig.  3F) suggests that there may be additional factors contributing to the complex relationship between TTI and mortality.
Limitations
The current study has several limitations. Similar to all registries, the NCBD inherently carries the potential for selection, information, and recall bias, as well as unmeasured confounding. The NCDB is restricted to hospitalbased data and therefore may not reflect the practice patterns of outpatient community facilities. Although we used strict inclusion criteria to produce the cohorts for the analyses in the current study, the generalizability of our findings is uncertain; further analyses using additional population-based data sets could be instrumental in validating the current study results. Despite the size of the NCDB, its power was limited in this analysis to determine trends in outcomes after extended TTI, as evidenced by the increasingly wide 95% CIs in Figures 2 and 3D to 3F. The NCDB includes only OS as an endpoint, which precludes further understanding of cancer-specific outcomes. Finally, because the analysis in the current study relied on pathologic staging to confirm upstaging, we were unable to use upstaging as a variable to represent tumor progression when assessing those patients treated nonoperatively. Despite this, we would expect that extended TTI similarly has an adverse effect on patients receiving RT or CRT alone, especially given the established finding that patients receiving RT or CRT alone require a TTI that is nearly double the TTI for those receiving surgery.
5,14
Conclusions
For patients with HNSCC, pathologic upstaging is a poor prognostic factor. Upstaging occurs at a baseline rate attributable to inaccuracies in clinical staging, but the odds of upstaging increase significantly with increasing TTI, suggesting tumor progression. TTI is a modifiable risk factor and appears to be a valid metric of high-quality cancer care. Upstaging was found to be associated with increased mortality, and it appears to be the primary driver of the complex relationship between increased TTI and increased mortality. When surgery is planned for patients with HNSCC, timely intervention during the first 4 weeks after diagnosis is critical to minimize tumor progression and optimize survival.
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